{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T04:36:54Z","timestamp":1764131814817,"version":"3.46.0"},"reference-count":26,"publisher":"Georg Thieme Verlag KG","issue":"02","funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung\n                    und Forschung","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Padiatr"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background Pseudomonas aeruginosa (Pa) continues to affect disease\n                    progression in cystic fibrosis (CF). However, the best eradication regimen\n                    remains unclear. This work compares three different antibiotic eradication\n                    regimens in pediatric CF: an administration according to a standard-operating\n                    procedure (SOP) order vs. administration outside of this order (ooSOP).<\/jats:p>\n                  <jats:p>Methods This observational study includes all CF patients&lt;18 years\n                    who received one of three Pa eradication treatments in the past eight years at\n                    our center: 1) inhaled high-dose tobramycin (Hi-TOBI), 2) inhaled\n                    colistin+oral ciprofloxacin (COL\/Cip), 3) inhaled low-dose\n                    tobramycin+4 intravenous 14-day Pa active antibiotic treatments\n                    (lo-Tobra\/IV). We compared eradication rates of the three treatment\n                    regimens performed according to the SOP-based order vs. ooSOP. Logistic\n                    regression analysis was performed to identify risk factors for eradication\n                    failure.<\/jats:p>\n                  <jats:p>Results Performed according to SOP order, Hi-TOBI showed the greatest\n                    efficacy, followed by lo-Tobra\/IV and finally COL\/Cip, while\n                    ooSOP lo-Tobra\/IV was most successful, followed by COL\/Cip and\n                    Hi-TOBI. Previous Pa-infections and Pa-therapies along with age at CF diagnosis\n                    were risk factors for eradication failure.<\/jats:p>\n                  <jats:p>Conclusion Antibiotic treatment in SOP-based pre-defined order leads to\n                    significantly better eradication rates than individual modifications of the\n                    order of administration. A short course of inhalational high-dose Tobramycin is\n                    most successful at the first attempt. Prolonged antibiotic therapy seems to\n                    improve eradication after failed initial attempts.<\/jats:p>","DOI":"10.1055\/a-1996-0074","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T18:51:22Z","timestamp":1675968682000},"page":"75-83","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Three Eradication Treatment Protocols for Pseudomonas\n                    Aeruginosa in Children and Adolescents with Cystic Fibrosis"],"prefix":"10.1055","volume":"235","author":[{"given":"Katharina","family":"Sch\u00fctz","sequence":"additional","affiliation":[{"name":"Dep. of Paediatric Pneumology, Allergy and Neonatology, Hannover\n                    Medical School, Hannover, Germany"},{"name":"Excellence Cluster RESIST \u2013 Resolving Infection Susceptibility,\n                    Hannover Medical School, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Grewendorf","sequence":"additional","affiliation":[{"name":"Dep. of Paediatric Pneumology, Allergy and Neonatology, Hannover\n                    Medical School, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Kontsendorn","sequence":"additional","affiliation":[{"name":"Dep. of Paediatric Pneumology, Allergy and Neonatology, Hannover\n                    Medical School, Hannover, Germany"},{"name":"German Center for Lung Research, BREATH location, Hannover Medical\n                    School, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Fuge","sequence":"additional","affiliation":[{"name":"German Center for Lung Research, BREATH location, Hannover Medical\n                    School, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Happle","sequence":"additional","affiliation":[{"name":"Dep. of Paediatric Pneumology, Allergy and Neonatology, Hannover\n                    Medical School, Hannover, Germany"},{"name":"Excellence Cluster RESIST \u2013 Resolving Infection Susceptibility,\n                    Hannover Medical School, Hannover, Germany"},{"name":"German Center for Lung Research, BREATH location, Hannover Medical\n                    School, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isa","family":"Rudolf","sequence":"additional","affiliation":[{"name":"Dep. of Paediatric Pneumology, Allergy and Neonatology, Hannover\n                    Medical School, Hannover, Germany"},{"name":"German Center for Lung Research, BREATH location, Hannover Medical\n                    School, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Dopfer","sequence":"additional","affiliation":[{"name":"Dep. of Paediatric Pneumology, Allergy and Neonatology, Hannover\n                    Medical School, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludwig","family":"Sedlacek","sequence":"additional","affiliation":[{"name":"Institute for Medical Microbiology and Hospital Epidemiology, Hannover\n                    Medical School, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gesine","family":"Hansen","sequence":"additional","affiliation":[{"name":"Dep. of Paediatric Pneumology, Allergy and Neonatology, Hannover\n                    Medical School, Hannover, Germany"},{"name":"Excellence Cluster RESIST \u2013 Resolving Infection Susceptibility,\n                    Hannover Medical School, Hannover, Germany"},{"name":"German Center for Lung Research, BREATH location, Hannover Medical\n                    School, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibylle","family":"Junge","sequence":"additional","affiliation":[{"name":"Dep. of Paediatric Pneumology, Allergy and Neonatology, Hannover\n                    Medical School, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Maria","family":"Dittrich","sequence":"additional","affiliation":[{"name":"Dep. of Paediatric Pneumology, Allergy and Neonatology, Hannover\n                    Medical School, Hannover, Germany"},{"name":"German Center for Lung Research, BREATH location, Hannover Medical\n                    School, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1183\/09031936.00166412","article-title":"Factors associated with FEV1 decline in cystic fibrosis: Analysis of the ECFS\n                    patient registry","volume":"43","author":"E Kerem","year":"2014","journal-title":"Eur Respir J"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/ppul.23715","article-title":"Risk factors for mortality before age 18 years in cystic fibrosis","volume":"52","author":"S A McColley","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ppul.21525","article-title":"EPIC Investigators. Initial pseudomonas aeruginosa treatment failure is\n                    associated with exacerbations in cystic fibrosis","volume":"47","author":"N Mayer-Hamblett","year":"2012","journal-title":"Pediatr Pulmonol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(01)06124-4","article-title":"Effect of inhaled tobramycin on early pseudomonas aeruginosa colonisation in\n                    patients with cystic fibrosis","volume":"358","author":"F Ratjen","year":"2001","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2012.06.001","article-title":"Comparison of two treatment regimens for eradication of pseudomonas aeruginosa\n                    infection in children with cystic fibrosis","volume":"12","author":"M Proesmans","year":"2013","journal-title":"J Cyst Fibros"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/archpediatrics.2011.136","article-title":"Comparative efficacy and safety of 4 randomized regimens to treat early\n                    pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"165","author":"M M Treggiari","year":"2011","journal-title":"Arch Pediatr Adolesc Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/thoraxjnl-2011-200832","article-title":"Italian Group for P aeruginosa Eradication in Cystic Fibrosis. Early antibiotic\n                    treatment for pseudomonas aeruginosa eradication in patients with cystic\n                    fibrosis: A randomised multicentre study comparing two different protocols","volume":"67","author":"G Taccetti","year":"2012","journal-title":"Thorax"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cct.2009.01.003","article-title":"EPIC Study Group. Early anti-pseudomonal acquisition in young patients with\n                    cystic fibrosis: Rationale and design of the EPIC clinical trial and\n                    observational study\u2019","volume":"30","author":"M M Treggiari","year":"2009","journal-title":"Contemp Clin Trials"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jcf.2004.03.008","article-title":"Consensus Study Group. Early intervention and prevention of lung disease in\n                    cystic fibrosis: A european consensus","volume":"3","author":"G Doring","year":"2004","journal-title":"J Cyst Fibros"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/(SICI)1099-0496(199802)25:2<88::AID-PPUL3>3.0.CO;2-J","article-title":"von der Hardt H. Placebo-controlled, double-blind, randomized study of\n                    aerosolized tobramycin for early treatment of pseudomonas aeruginosa\n                    colonization in cystic fibrosis","volume":"25","author":"H G Wiesemann","year":"1998","journal-title":"Pediatr Pulmonol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jcf.2017.01.007","article-title":"Effectiveness of a stepwise pseudomonas aeruginosa eradication protocol in\n                    children with cystic fibrosis","volume":"16","author":"A C Blanchard","year":"2017","journal-title":"J Cyst Fibros"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jcf.2013.09.002","article-title":"Effectiveness of inhaled tobramycin in eradicating pseudomonas aeruginosa in\n                    children with cystic fibrosis","volume":"13","author":"S Stanojevic","year":"2014","journal-title":"J Cyst Fibros"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0140-6736(91)91446-2","article-title":"Prevention of chronic pseudomonas aeruginosa colonisation in cystic fibrosis by\n                    early treatment","volume":"338","author":"N H Valerius","year":"1991","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jcf.2014.06.003","article-title":", ALPINE study investigators. Open label study of inhaled aztreonam for\n                    pseudomonas eradication in children with cystic fibrosis: The ALPINE study","volume":"14","author":"H A Tiddens","year":"2015","journal-title":"J Cyst Fibros"},{"key":"ref18","first-page":"CD004197","article-title":"Antibiotic strategies for eradicating pseudomonas aeruginosa in people with\n                    cystic fibrosis","volume":"4","author":"S C Langton Hewer","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2213-2600(20)30331-3","article-title":"TORPEDO-CF study group. Intravenous versus oral antibiotics for eradication of\n                    pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): A randomised controlled\n                    trial","volume":"8","author":"SC L Hewer","year":"2020","journal-title":"Lancet Respir Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/thx.2009.121657","article-title":"ELITE Study Group. Treatment of early pseudomonas aeruginosa infection in\n                    patients with cystic fibrosis: The ELITE trial","volume":"65","author":"F Ratjen","year":"2010","journal-title":"Thorax"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1183\/20734735.012717","article-title":"The global lung function initiative (GLI) network: Bringing the world\u2019s\n                    respiratory reference values together","volume":"13","author":"B G Cooper","year":"2017","journal-title":"Breathe (Sheff)"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s001120170107","article-title":"Perzentile f\u00fcr den Body-mass-index f\u00fcr das Kindes- und\n                    Jugendalter unter Heranziehung verschiedener deutscher Stichproben","volume":"149","author":"K Kromeyer-Hauschild","year":"2001","journal-title":"Monatsschrift Kinderheilkunde"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jcf.2012.04.003","article-title":"EPIC Study Group. Risk factors for age at initial pseudomonas acquisition in the\n                    cystic fibrosis epic observational cohort","volume":"11","author":"M Rosenfeld","year":"2012","journal-title":"J Cyst Fibros"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ppul.10230","article-title":"Risk factors for initial acquisition of pseudomonas aeruginosa in children with\n                    cystic fibrosis identified by newborn screening","volume":"35","author":"J H Maselli","year":"2003","journal-title":"Pediatr Pulmonol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1183\/09031936.00043108","article-title":"Acquisition and eradication of P. aeruginosa in young children with cystic\n                    fibrosis","volume":"33","author":"T A Douglas","year":"2009","journal-title":"Eur Respir J"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2213-2600(20)30331-3","article-title":"TORPEDO-CF study group. Intravenous versus oral antibiotics for eradication of\n                    pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): A randomised controlled\n                    trial","volume":"8","author":"SC L Hewer","year":"2020","journal-title":"Lancet Respir Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/jcpt.12407","article-title":"The success of the different eradication therapy regimens for pseudomonas\n                    aeruginosa in cystic fibrosis","volume":"41","author":"N Emiralioglu","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10096-015-2509-4","article-title":"Chronic infection phenotypes of pseudomonas aeruginosa are associated with\n                    failure of eradication in children with cystic fibrosis","volume":"35","author":"P Vidya","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/jama.293.5.581","article-title":"Longitudinal development of mucoid pseudomonas aeruginosa infection and lung\n                    disease progression in children with cystic fibrosis","volume":"293","author":"Z Li","year":"2005","journal-title":"Jama"}],"container-title":["Klinische P\u00e4diatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1996-0074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T04:28:27Z","timestamp":1764131307000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1996-0074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":26,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2023,3,9]]},"published-print":{"date-parts":[[2023,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1996-0074","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0300-8630","1439-3824"],"issn-type":[{"type":"print","value":"0300-8630"},{"type":"electronic","value":"1439-3824"}],"subject":[],"published":{"date-parts":[[2023,2,9]]}}}